ALSO NOTED: Investors to pay $1.3 billion for Axcan; Smith & Nephew recalls knee implants;

> Canada's Axcan Pharma has agreed to a buyout by the private equity firm TPG Capital for $1.3 billion. Release

> Device maker Smith & Nephew is recalling some 600 knee implants that may contain too much iron; about 275 of the devices have already been implanted into patients. Report

> Germany's Merck KgaA won approval from the European Commission to sell a treatment kit for cyanide poisoning. Report

> Health Canada gave its blessing to Cangene's liquid formulation of a blood-disorder drug used in infants. Report

> The Chinese government announced that it intends to impose heavy punishments on makers of counterfeit drugs; in some cases, this may include the death penalty. Report

And Finally... A doctors' group wants to standardize and simplify prescription labels to make sure patients understand when and how to take their medicine. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.